It is not yet approved, and this does not mean we have “cured cancer.” But it is an extraordinary proof of concept: sequencing + AI/computational biology + mRNA + immunotherapy can be combined to create a treatment tailored to the genetic fingerprint of an individual patient’s tumor.

Moderna and Merck said on Wednesday that a personalized mRNA cancer vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment that sent Moderna’s shares surging as much ‌as 160%.